表紙
市場調査レポート

聴覚障害 - パイプライン製品の分析

Hearing Disorders - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 245983
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
聴覚障害 - パイプライン製品の分析 Hearing Disorders - Pipeline Review, H2 2014
出版日: 2014年11月30日 ページ情報: 英文 94 Pages
概要

聴覚障害は、聞こえなくなるのではなく、聞くのに困難をきたすという疾患です。難聴、競合する音声や背景に雑音がある場合に会話の理解ができない、誰かが話しているのは聞こえるが単語が聞き取れない、以前よりTVやラジオの音声を大きくする、会話や社会的な交流を避けるといった症状があります。年齢、騒音、ある種の薬剤、心臓病、高血圧、糖尿病といった疾患が発病要因となる場合があります。

当レポートでは、聴覚障害に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

聴覚障害の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Adherex Technologies Inc.
  • Quark Pharmaceuticals, Inc.
  • Novartis AG
  • Living Cell Technologies Limited
  • Fate Therapeutics, Inc.
  • Sound Pharmaceuticals, Inc.
  • Pharmicell Co., Ltd.
  • Otologic Pharmaceutics, Inc.
  • UniQure NV
  • AudioCure Pharma GmbH

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • sodium thiosulfate
  • SPI-1005
  • ebselen
  • CGF-166
  • AUT-00063
  • siRNA for CNS Disorders
  • AMT-090
  • SPI-5557
  • NTCELL
  • Hearing Restoration Program
  • Small Molecules for Hearing Loss
  • (acetylcysteine + disufenton sodium)
  • Neuroprotectin D1
  • AC-002
  • Cellgram for Severe Hard of Hearing
  • Drugs to Inhibit Rho Kinase for Hearing Loss

パイプライン製品の最新動向

休止中のプロジェクト

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5811IDB

Summary

Global Markets Direct's, 'Hearing Disorders - Pipeline Review, H2 2014', provides an overview of the Hearing Disorders's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hearing Disorders
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hearing Disorders and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hearing Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hearing Disorders pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hearing Disorders
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hearing Disorders Overview
  • Therapeutics Development
    • Pipeline Products for Hearing Disorders - Overview
    • Pipeline Products for Hearing Disorders - Comparative Analysis
  • Hearing Disorders - Therapeutics under Development by Companies
  • Hearing Disorders - Therapeutics under Investigation by Universities/Institutes
  • Hearing Disorders - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hearing Disorders - Products under Development by Companies
  • Hearing Disorders - Products under Investigation by Universities/Institutes
  • Hearing Disorders - Companies Involved in Therapeutics Development
    • Affichem
    • AudioCure Pharma GmbH
    • Edison Pharmaceuticals, Inc.
    • Fate Therapeutics, Inc.
    • Living Cell Technologies Limited
    • Novartis AG
    • Otologic Pharmaceutics, Inc.
    • Pharmicell Co., Ltd.
    • Quark Pharmaceuticals, Inc.
    • Sound Pharmaceuticals, Inc.
    • uniQure NV
  • Hearing Disorders - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (acetylcysteine + disufenton sodium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AF-243 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMT-090 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AUT-00063 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellgram for Severe Hard of Hearing - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGF-166 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Rho Kinase for Hearing Loss - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neuroprotectin D1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NTCELL - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OT-0001 Analogs - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-13 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siRNA for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sodium thiosulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-1005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-3005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-5557 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Hearing Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • transplatin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hearing Disorders - Recent Pipeline Updates
  • Hearing Disorders - Dormant Projects
  • Hearing Disorders - Discontinued Products
  • Hearing Disorders - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2014: Adherex Announces Results From Two Sodium Thiosulfate Phase 3 Studies Presented at the 50th American Society of Clinical Oncology Meeting
      • Apr 22, 2014: Adherex Announces Two Sodium Thiosulfate Presentations for Prevention of Ototoxicity in Children at ASCO Meeting
      • Nov 05, 2013: Sound Pharmaceuticals successfully completes its first Phase 2 clinical trial with SPI-1005 involving iPod or noise induced hearing loss
      • Oct 07, 2011: Adherex Reports Meeting With FDA'S Pediatric Subcommittee Of Oncologic Drugs Advisory Committee On Development Of Sodium Thiosulfate Injection
      • Jun 28, 2010: Fate Therapeutics Receives Red Herring's North America 100 Award For Advancing Stem Cell Technology And New Medicines
      • Feb 04, 2010: Fate Therapeutics Receives Allowance Of First U.S. Patent For Induced Pluripotent Stem Cell Technology
      • Dec 01, 2009: Fate Therapeutics' IPSC Technology Awarded Top Industry Honors For Small Molecule And Protein Reprogramming Breakthroughs
      • Nov 16, 2009: Fate Therapeutics Closes $30 Million Series B Financing
      • Aug 19, 2009: Sound Pharmaceuticals Receives An Office of Naval Research Award for Its Hearing Loss Research and Development
      • Jul 23, 2008: Sound Pharmaceuticals Files Second IND with the FDA For The Prevention Of Chemotherapy Induced Hearing Loss In Advanced Stage Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hearing Disorders, H2 2014
  • Number of Products under Development for Hearing Disorders - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Hearing Disorders - Pipeline by Affichem, H2 2014
  • Hearing Disorders - Pipeline by AudioCure Pharma GmbH, H2 2014
  • Hearing Disorders - Pipeline by Edison Pharmaceuticals, Inc., H2 2014
  • Hearing Disorders - Pipeline by Fate Therapeutics, Inc., H2 2014
  • Hearing Disorders - Pipeline by Living Cell Technologies Limited, H2 2014
  • Hearing Disorders - Pipeline by Novartis AG, H2 2014
  • Hearing Disorders - Pipeline by Otologic Pharmaceutics, Inc., H2 2014
  • Hearing Disorders - Pipeline by Pharmicell Co., Ltd., H2 2014
  • Hearing Disorders - Pipeline by Quark Pharmaceuticals, Inc., H2 2014
  • Hearing Disorders - Pipeline by Sound Pharmaceuticals, Inc., H2 2014
  • Hearing Disorders - Pipeline by uniQure NV, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Hearing Disorders Therapeutics - Recent Pipeline Updates, H2 2014
  • Hearing Disorders - Dormant Projects, H2 2014
  • Hearing Disorders - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Hearing Disorders, H2 2014
  • Number of Products under Development for Hearing Disorders - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top